

# Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation

Melinda A. Biernacki,<sup>1,2</sup> Yu-tzu Tai,<sup>3,4</sup> Guang Lan Zhang,<sup>2</sup> Anselmo Alonso,<sup>2</sup> Wandi Zhang,<sup>2</sup> Rao Prabhala,<sup>3,4</sup> Li Zhang,<sup>2,3</sup> Nikhil Munshi,<sup>3,5</sup> Donna Neuberg,<sup>6</sup> Robert J. Soiffer,<sup>3,4</sup> Jerome Ritz,<sup>2,4</sup> Edwin P. Alyea,<sup>3,4</sup> Vladimir Brusic,<sup>2</sup> Kenneth C. Anderson,<sup>3,4</sup> and Catherine J. Wu<sup>2,4</sup>

<sup>1</sup>University of Connecticut School of Medicine, Farmington, CT; <sup>2</sup>Cancer Vaccine Center and <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; <sup>4</sup>Department of Medicine, Harvard Medical School, Boston, MA; <sup>5</sup>Veterans Administration Boston Healthcare System, West Roxbury, MA; and <sup>6</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

**Targets of curative donor-derived graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against minor histocompatibility Ags (mHAg)s complicates the elucidation of multiple myeloma (MM)-specific targets. We hypothesized that syngeneic HSCT would facilitate the identification of GVM-associated Ags because donor immune responses in this setting should exclusively target unique tumor Ags in the absence of donor-host**

**genetic disparities. Therefore, in the present study, we investigated the development of tumor immunity in an HLA-A\*0201<sup>+</sup> MM patient who achieved durable remission after myeloablative syngeneic HSCT. Using high-density protein microarrays to screen post-HSCT plasma, we identified 6 Ags that elicited high-titer (1:5000-1:10 000) Abs that correlated with clinical tumor regression. Two Ags (DAPK2 and PIM1) had enriched expression in primary MM tissues. Both elicited Ab responses in other MM patients after**

**chemotherapy or HSCT (11 and 6 of 32 patients for DAPK2 and PIM1, respectively). The index patient also developed specific CD8<sup>+</sup> T-cell responses to HLA-A\*2-restricted peptides derived from DAPK2 and PIM1. Peptide-specific T cells recognized HLA-A\*2<sup>+</sup> MM-derived cell lines and primary MM tumor cells. Coordinated T- and B-cell immunity develops against MM-associated Ags after syngeneic HSCT. DAPK1 and PIM1 are promising target Ags for MM-directed immunotherapy. (*Blood*. 2012;119(13):3142-3150)**

## Introduction

Clinical studies over the last 2 decades have highlighted the critical contribution of donor-derived immunity against tumors to the long-term curative effects of allogeneic hematopoietic stem cell transplantation (HSCT).<sup>1</sup> The potency of this donor-derived graft-versus-tumor (GVT) response is clearly illustrated by the clinical success of therapies such as donor lymphocyte infusion<sup>2,3</sup> and reduced intensity HSCT,<sup>4,5</sup> which minimize or avoid chemo- and radiotherapy and rely instead on immunity to drive their antitumor effect.<sup>2-8</sup> The beneficial GVT effects associated with these responses, however, are typically associated with detrimental GVHD responses.<sup>7,9</sup> Preserving the benefits of GVT responses while minimizing toxicity from GVHD thus remains a critical unsolved issue in transplantation medicine.

Defining the target Ags of GVT and GVHD may provide insight into their mechanisms and suggest rational methods for their separation. Minor histocompatibility Ags (mHAgs) make up one major class of Ags against which potent donor-derived T- and B-cell immunity develops after HSCT. mHAgs with broad or nonhematopoietic cell expression are implicated in GVHD,<sup>10</sup> whereas those with restricted hematopoietic expression play a well-accepted role in GVT responses.<sup>10-12</sup> The extent to which nonpolymorphic tumor-associated Ags are targets is less well understood. Tumors may be distinguished from normal cells by genetic alterations, including chromosomal translocations. Tumors can also overexpress or aberrantly express genes compared with

their normal counterparts.<sup>13</sup> In support of the existence of immunogenic Ags with tumor-restricted expression, Nishida et al described T-cell immunity against leukemia cells after allogeneic HSCT that was not directed against mHAgs.<sup>14</sup> The discovery of such naturally immunogenic tumor-associated Ags (TAAs) could lead to the development of immunotherapeutic strategies to target tumor in a selective fashion and thus avoid GVHD toxicity.

Because allogeneic HSCT can result in durable curative remission, it provides a useful clinical backdrop for identifying Ags that are naturally immunogenic to normal donor cells. However, defining TAAs in the allogeneic setting can be complicated by the presence of alloimmune responses. In the present study, we describe a context in which effective donor-derived tumor immunity occurred in the absence of alloimmunity: myeloablative syngeneic HSCT resulting in durable molecular remission in an individual with multiple myeloma (MM). Dissecting humoral immune responses by serologic screening after immune-mediated therapy<sup>15-18</sup> or in premalignant conditions<sup>19</sup> has been a successful strategy for identifying TAAs. We therefore examined the B-cell responses developing in this index patient. By screening plasma samples after HSCT against high-density protein microarrays, we identified 2 Ags, DAPK2 and PIM1, which elicited high-titer plasma Ab responses that were coordinated with Ag-specific CD8<sup>+</sup> T-cell immunity. Consistent with the notion that these Ags are myeloma-specific targets, we found that peptides derived from

Submitted November 11, 2011; accepted December 27, 2011. Prepublished online as *Blood* First Edition paper, January 20, 2012; DOI 10.1182/blood-2011-11-388926.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

these Ags further elicited T-cell responses against HLA-A2<sup>+</sup> MM cell lines and primary MM plasma cells. Our results suggest a key role for TAAs that is distinct from mHAgS and that can elicit coordinated T- and B-cell responses to effect GVM immunity.

## Methods

### Patient samples and cell preparation

Heparinized blood and BM samples were obtained from patients and healthy donors enrolled in clinical research protocols at the Dana-Farber Harvard Cancer Center approved by the Human Subjects Protection Committee. BM mononuclear cells (BMMCs) or PBMCs were isolated by Ficoll/Hypaque density-gradient centrifugation, cryopreserved with 10% DMSO, and stored in vapor-phase liquid nitrogen until the time of analysis. Plasma was isolated by removal of the plasma layer after centrifugation of whole blood and cryopreserved at  $-80^{\circ}\text{C}$  until the time of analysis.

### Cell lines, plasmids, and peptides

The MM cell lines IM-9, RPMI 8226, MC/CAR, and NCI-H929 were obtained from the American Type Culture Collection and lines OPM1 and OPM2 from Dr Ken Anderson (Dana-Farber Cancer Institute). DNA sequences encoding candidate Ags were acquired from the Dana-Farber Cancer Institute Center for Cancer Systems Biology Human ORFeome Collection (Dr Mark Vidal, Dana-Farber Cancer Institute), or from the PlasmID repository (Dr Joshua LaBaer, Harvard Institute of Proteomics) and cloned into the pDONR221 Gateway vector (Invitrogen). The inserts of all of the acquired plasmids were verified by sequencing and then shuttled into a Gateway-converted mammalian expression vector containing a T7 promoter and a C-terminus GST tag (Wagner Montor, Harvard Institute of Proteomics) using LR Clonase (Invitrogen). DAPK2 and PIM1 were PCR cloned into pcDNA3 using the following primers: PIM1 forward, 5'-AAGG AAGCTT ATGCTCTGTCCAAAATC-3', reverse, 5'-CCGG GAATTC CTATTTGCTGGGCCCG-3'; and DAPK2 forward, 5'-AAGG GGATCC ATGTTCCAGGCCTCAAT-3', reverse, 5'-CCGG CTCGAG TTAGGAG-GTGCTGCTC-3'. Synthetic peptides encoding the influenza M1<sub>58-66</sub> epitope (FluM1, GILGFVFTL) and predicted HLA-A2<sup>+</sup>-binding 9-mer peptides derived from DAPK2 and PIM1 were obtained from New England Peptide.

### Serologic screening using high-density protein microarrays

Commercial protein microarrays (Human ProtoArray Version 4; Invitrogen) were probed with plasma samples as described previously.<sup>20</sup> All samples were screened using arrays from the same printing lot. The microarrays contained approximately 8000 N-terminus GST-fusion human proteins expressed in an insect cell line and spotted on nitrocellulose-coated glass slides. The protein microarrays were processed at 4°C according to the manufacturer's recommendations. In brief, after blocking, patient plasma (diluted 1:150) was applied to the microarray surface for 90 minutes, and Ab-Ag interactions were detected with Alexa Fluor 647-conjugated anti-human IgG (H and L chain) Ab (1:2000; Invitrogen). Lot-specific protein spot definitions provided by the microarray manufacturer were manually aligned to the image data. Fluorescence intensities were quantified using GenePix Pro Version 5.0 software (Molecular Devices) at 635 nm, 100% power, and 600 gain. Significant Ab-protein interactions were determined using Prospector Version 5.1.0 analysis software (Invitrogen) and an algorithm<sup>20</sup> that incorporates the contribution of protein spot concentration to signal intensity. Signal change between pre-treatment or control plasma and post-treatment plasma was considered significant if the change in both (1) the signal magnitude ( $Z_{\text{delta}}$ ), defined as  $Z_{\text{post}} - \max(0, Z_{\text{pre}})$  and (2) the ratio ( $Z_{\text{multi}}$ ), defined as  $Z_{\text{post}}/\max(1, Z_{\text{pre}})$ , were greater than a cutoff value  $n$  ( $n = 5$  for significant Ags, called "candidate Ags"). All candidate Ags selected for the final analysis had significantly higher reactivity at the maximum post-HSCT time point compared with 2 normal controls, the patient's donor, and a prechemotherapy patient sample.

### Validation and survey of Ag-specific Ab responses to candidate Ags

We first validated the results of serologic screening using an immunoprecipitation-based method.<sup>21</sup> In brief, candidate Ags in the pCITE mammalian expression vector were transcribed and translated in vitro with rabbit reticulocyte lysate (TNT T7 Quick Coupled Transcription/Translation; Promega) using biotinylated lysine transfer RNA (Transcend tRNA; Promega). Expressed protein was immunoprecipitated using patient plasma, as described previously.<sup>20</sup> Immunoprecipitated proteins were subjected to SDS-PAGE on 10% Tris-HCl polyacrylamide gels (Bio-Rad), transferred to nitrocellulose membranes in Tris-glycine buffer with 20% methanol (blocked overnight in 1× TBS/0.5% Tween-20), and detected using streptavidin-HRP conjugate (1:20 000 dilution; MP Biomedicals).

We further developed ELISA assays in which recombinant DAPK2 and PIM1 proteins, expressed in a baculovirus-infected insect cell line (Ultimate ORF Collection; Invitrogen) were applied at 5 μg/mL to Nunc C96 Maxisorp plates (Fisher Scientific) in carbonate buffer (pH 9.6) overnight at 4°C, then blocked in PBS with 0.05% Tween plus 2% milk. Plasma samples were added to duplicate wells in blocking buffer (1:200 dilution) and incubated for 3 hours at 25°C. Binding of patient Ig to test proteins was detected using goat anti-human IgG-alkaline phosphatase secondary Ab (1:1000 dilution, Jackson ImmunoResearch Laboratories) and visualized with *p*-nitrophenyl phosphate substrate (Sigma-Aldrich). Absorbance was read at 405 nm. Samples were defined as Ag reactive if the signal was greater than 2 SDs above the mean of 10 normal volunteers.

### Quantitative PCR for molecular detection of disease and for gene expression

The clonotypic IgH sequence of patient A was identified using a panel of VH-specific PCR primers, as described previously.<sup>22</sup> Based on this sequence, a quantitative TaqMan PCR assay was designed such that a sequence-specific probe was located in the region of junctional diversity (Applied Biosystems). This assay was applied to reverse-transcribed RNA (SuperScript II reverse transcriptase; Invitrogen) isolated from PBMCs, BMMCs, or CD138<sup>+</sup>-selected (Miltenyi Biotec) BMMCs (RNeasy kit; QIAGEN).

Direct quantification of gene expression of candidate Ags was performed using gene-specific TaqMan Gene Expression Assays (Applied Biosystems), applied to reverse-transcribed RNA (RNeasy; QIAGEN) from total PBMCs immunomagnetically selected CD19<sup>+</sup> cells from healthy donors (Miltenyi Biotec) or from BMMCs of MM patients (> 95% malignant plasma cells by immunohistochemistry). All PCR reactions consisted of: 50°C for 1 minute for 1 cycle, 95°C for 10 minutes for 1 cycle, and 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute (7500 Fast Real-time PCR cycler; Applied Biosystems). Test transcripts were quantified relative to GAPDH transcripts by calculating  $2 \times (\text{GAPDH } C_T - \text{target } C_T)$ . The statistical significance between sample groups was determined by 1-sided exact Wilcoxon rank-sum test.

### Generation of cell lysates and Western blotting

Whole-cell lysate was generated from tumor cell lines or from patient samples by lysis with RIPA buffer (1% NP40, 0.5% deoxycholate, 0.1% SDS, 125mM sodium chloride, 50mM HEPES, pH 7.4) in the presence of protease inhibitors. Lysates (20 μg of total protein per lane) were subjected to 4%-15% gradient SDS-PAGE in Tris-glycine buffer, and transferred onto nitrocellulose membranes in Tris-glycine buffer containing 20% methanol. Rabbit polyclonal DAPK2 Ab (1:1000; ProSci) and mouse PIM1 mAb (clone 12H8, 1:1000; Santa Cruz Biotechnology) were used for Western blotting. Ab to β-actin (1:3000; Sigma-Aldrich) was used as a control to ensure equal loading of lanes.

### Generation of APCs

To generate dendritic cells, CD14<sup>+</sup> cells were isolated from leukapheresis material by immunomagnetic enrichment (Miltenyi Biotec), and cultured in the presence of 50 ng/mL of GM-CSF (Genzyme) and 20 ng/mL of IL-4 (R&D Systems) in medium composed of IMDM (Invitrogen) supplemented

**Table 1. Clinical characteristics of patient A**

Age/ sex	Time from diagnosis to HSCT, mo	Therapies prior to HSCT	HSCT conditioning regimen	Stem cell dose, cells/kg body wt	Stem cell source	Time from HSCT to complete response, mo*	Time from HSCT to molecular response, mo
48/F	108	Lenalidomide, bortezomib, dexamethasone	High-dose melphalan	$6.85 \times 10^6$	PBSCs	2.6	24

\*Defined as negative immunofixation and monoclonal protein of 0 g/dL.  
PBSCs indicates peripheral blood stem cells.

with 10% human AB serum (Cellgro), 2mM glutamine (Cellgro), 50  $\mu$ g/mL of human transferrin (Roche), 5  $\mu$ g/mL of human insulin (Sigma-Aldrich), and 15  $\mu$ g/mL of gentamycin (Invitrogen). On days 3 and 6, 50% fresh medium with cytokines was added. On day 7, cells were matured for 48 hours with prostaglandin E2 (1  $\mu$ g/mL; Sigma-Aldrich), IL-1 $\alpha$  (10 ng/mL; BD Biosciences), IL-6 (1000 U/mL; BD Biosciences), and TNF $\alpha$  (10 ng/mL; Genzyme). The TAP-deficient, HLA-A\*0201-expressing cell line T2 was obtained from Dr Peter Cresswell (Yale University School of Medicine, New Haven, CT). PIM1 and DAPK2 were expressed in APCs by nucleofecting 20  $\mu$ g of DNA plasmids encoding these genes into  $2 \times 10^6$  cells K562 cells, stably expressing HLA-A\*0201 in 100  $\mu$ L of PBS/10% HEPES buffer (Amaya Nucleofector, Program T-016; Lonza). For some experiments, HLA class I-blocking Ab was used (clone w6/32).

### T2-binding assay

The prediction servers IEDB ANN, NetMHC ANN, and MHC-I Multiple Matrix were used to predict HLA-A\*0201-binding nonameric peptides derived from DAPK2 and PIM1. Synthesized peptides were tested for their HLA-A2-binding ability using the T2-binding assay.<sup>23</sup> In brief, 1 million T2 cells per condition were washed extensively with serum-free IMDM (Invitrogen) and then incubated in serum-free IMDM with or without individual predicted peptides or the influenza M1 peptide at 40  $\mu$ M. Cells were harvested at 0 and 24 hours, stained with FITC-labeled mouse anti-HLA-A\*0201 (clone BB7.2; BD Pharmingen), and fixed in 2% formalin overnight. Fixed cells were analyzed by flow cytometry (FACSCanto II; BD Biosciences) to obtain the mean fluorescence intensity (MFI) of 10 000 events. Fluorescence index was calculated as follows: (MFI with peptide – MFI without peptide)/(MFI without peptide).

### Detection of DAPK2 and PIM1-specific T-cell responses

Patient reactivity to peptides was tested by ex vivo stimulation using total PBMCs isolated from fresh patient blood collected after HSCT. One to 2 million PBMCs were stimulated with 10  $\mu$ M concentrations of individual peptides in the presence of 10  $\mu$ g/mL of IL-7 for 7 days, and then tested by ELISpot assay. These peptides included the DAPK2-derived peptide D1<sub>156-164</sub>, (MLLDKNIPI) and the PIM1-derived peptide P4<sub>191-199</sub> (ALLK-DTVYT). For some experiments, banked PBMCs were thawed and stimulated with irradiated T2 cells, pulsed with 10  $\mu$ g/mL of D1 or P4 peptide in RPMI 1640 (Invitrogen) supplemented with 10% human AB serum (Cellgro), 2mM glutamine (Cellgro), 10mM HEPES (Cellgro), and 15  $\mu$ g/mL of gentamycin (Invitrogen) in the presence of 10 ng/mL of IL-7 (Endogen). ELISpot was performed using autologous matured dendritic cells pulsed with 10  $\mu$ M peptide (20 000 cells/well) co-incubated with the stimulated PBMCs (20 000 cells/well) plated in duplicate on Multi-Screen-IP plates (Millipore) for 24 hours. IFN- $\gamma$  secretion was detected using capture and detection Abs as directed by the manufacturer (Mabtech) and imaged using an ImmunoSpot Series Analyzer (Cellular Technology). Ag-specific reactivity was also detected by staining of cells with PE-conjugated peptide-specific tetramer (provided by the National Institutes of Health Tetramer Core Facility, Emory University), together with anti-CD8-FITC (Beckmann Coulter) and analyzed by flow cytometry (FACSAria II, BD Biosciences).

### Generation and testing of D1- and P4-specific T-cell lines

Patient PBMCs were thawed and stimulated weekly for 28 days with irradiated T2 cells (5000 rad) pulsed with 10  $\mu$ g/mL of peptides D1 or P4.

One week after the second stimulation, CD8<sup>+</sup> T cells were immunomagnetically selected (Miltenyi Biotec) for reculturing. One week after the fourth restimulation, peptide-specific tetramer-reactive T cells were sorted by flow cytometry and expanded on irradiated (5000 rad) allogeneic PBMCs and EBV-LCL feeder cells in the presence of 10  $\mu$ L/mL of phytohemagglutinin (Invitrogen) and 100 IU/mL of IL-2 (Novartis). Specificity of the T-cell lines was confirmed by testing with P4- and D1-specific tetramers and by ELISpot. To determine the responses of peptide-specific T cells against tumors, 50 000 cells from the BM of primary MM patients, from healthy donors, or from the MM cell lines were used as T-cell targets for the ELISpot assay. HLA-A2 status was confirmed by flow cytometry using the BB7.2 Ab.

## Results


### Complete molecular remission of MM after syngeneic HSCT for patient A

We identified a patient (patient A) who achieved complete molecular remission after syngeneic HSCT. As summarized in Table 1, this patient was a 48-year-old HLA-A2<sup>+</sup> woman with progressive stage II IgG MM diagnosed 9 years before HSCT. Before HSCT, she underwent induction with dexamethasone, lenalidomide, and bortezomib. At the time of HSCT, she demonstrated persistent residual disease with a serum monoclonal protein level of 0.6 g/dL and detectable monoclonal gammopathy on immunofixation (Figure 1A). After myeloablative conditioning with high-dose melphalan, the patient received CD34<sup>+</sup> peripheral blood stem cells ( $6.85 \times 10^6$  cells/kg) from her genotypically identical twin. At approximately 2.6 months after HSCT, neither serum monoclonal protein nor monoclonal gammopathy were detectable. Tumor-specific IgH transcripts remained detectable by quantitative real-time PCR of CD138<sup>+</sup> BM RNA, albeit with an almost 4-log reduction from pre-HSCT levels. However, as shown in Figure 1B, repeat analysis of total BMMCs from 24 to > 60 months after HSCT demonstrated continuing molecular remission. Having observed the effective elimination of MM in this patient, we sought to identify the tumor-associated Ags targeted by her syngeneic donor graft.

### Serologic screening identifies 6 candidate Ags, including DAPK2 and PIM1

We screened plasma samples from our index patient at 9 serial time points before and after HSCT against commercially available protein microarrays consisting of recombinant proteins expressed from approximately 8000 open reading frames in baculovirus-infected insect cell lines and spotted on glass slides. Binding of plasma Ab to spotted proteins was detected with fluorescently labeled anti-human IgG (Figure 2A). Negative controls included plasma from the patient's identical twin donor and from 2 age-, sex-, and parity-matched healthy controls. All 9 samples were





**Figure 1. Achievement of durable molecular remission after syngeneic HSCT for treatment of MM in patient A.** (A) Levels of serum monoclonal protein (g/dL) become undetectable by 1.5 months after HSCT. Arrows indicate the time points screened by protein microarray. Vertical dashed line indicates time of syngeneic stem cell infusion. (B) Expression of transcripts containing the IgH sequence unique to patient A's tumor is detectable by quantitative real-time PCR in BMMCs (black squares and solid line) and PBMCs (gray squares and line) before syngeneic HSCT, but is undetectable beginning at 24 months after HSCT. Values shown are tumor-specific IgH transcripts normalized to GAPDH transcript expression. "Undetectable" indicates samples with acceptable GAPDH values but absent tumor-specific IgH transcript expression.

screened in 2 replicates against 1 lot of protein microarrays. Significance of Ab binding to protein spots was determined using established analytical methods.<sup>20</sup> Candidate Ags were defined as

**Table 2. Candidate Ags identified by protein microarray screening**

Gene symbol*	NCBI gene ID	Chromosome	Size, aa	Maximum post-HSCT significance†	Maximum time point, mo
DAPK2	79098	1q32.1	370	+++	3
PIM1	23604	15q22.31	313	+++	3
PRKCB1	5159	5q31-q32	671	+++	3
C1orf116	5292	6p21.2	601	++	12
PDGFRB	5579	16p11.2	1106	++	12
RELA	5970	11q13	551	+	15

\*UniProt identifiers: DAPK2, Q1RMF4; PIM1 isoform 2, P11309-2; PRKCB1, P05771; C1orf116 (SARG), Q9BW04; PDGFRB, P09619; and RELA, Q04206.

†+ indicates 10- to 20-fold increase in significance (Z-score) of Ab binding in posttransplantation plasma; ++, 20- to 50-fold increase; and +++, > 50-fold increase.


those proteins eliciting significantly more plasma Ab binding from post-HSCT plasma compared with pre-HSCT plasma.


Six proteins (C1orf116, DAPK2, PDGFRB, PIM1, PRKCB1, and RELA) met the criteria for candidate Ags (Table 2). None elicited significant Ab reactivity from any of the 4 negative control plasma samples based on calculated Z-scores. The increase in significance (Z-score) of Ab binding for post-HSCT plasma was 17- to 10 615-fold higher than pre-HSCT Z-scores (Figure 2B). These significant Ag-specific Ab responses arose in 2 general patterns, early (peaking at 3 months: DAPK2, PIM1, and PRKCB1) or late (peaking at or after 12 months: C1orf116, PDGFRB, and RELA). We validated these statistical findings by confirming the detection of early- and late-peaking patterns of Ag-specific B-cell reactivity by measuring the amount of independently produced Ag immunoprecipitated by post-HSCT plasma-derived Ig from patient A (representative examples are shown in Figure 2C).

To more accurately quantify the immune responses against candidate Ags, we performed ELISA assays in which recombinant protein expressed in baculovirus-infected insect cell lines was used as a coating Ag. Using ELISA, the Ab responses against DAPK2

**Figure 2. Serologic screening identifies high-titer Ab responses against DAPK2, PDGFRB, PIM1, and PRKCB1 developing after syngeneic HSCT.**

(A) Plasma samples collected from patient A at serial time points before and after HSCT were screened by ProtoArray protein microarray. Subarrays demonstrating DAPK2 reactivity are highlighted in the gray boxes. Spots seen in the bottom right corner of all subarray images are control spots. (B) Arrays were analyzed using 2 methods described previously.<sup>48</sup> Six Ags, DAPK2, PDGFRB, C1orf116, RELA, PIM1, and PRKCB1, elicited significantly greater reactivity after HSCT compared with before HSCT. Significance (Z-scores) scores of Ab reactivity at time points are shown. (C) Ag binding was confirmed by immunoprecipitation of biotinylated target Ags expressed in vitro in rabbit reticulocyte lysate by patient plasma at serial time points. Immunoprecipitated Ags were detected using streptavidin-conjugated secondary Ab. Representative Western blots are shown. The first lane is whole rabbit reticulocyte lysate expressing target Ags that was not subjected to immunoprecipitation. (D) Plasma samples (1:200 dilution) collected from patient A at serial time points before and after HSCT were tested by ELISA (plates coated with 5  $\mu$ g/mL of recombinant protein). Ab IgG responses against DAPK2 and PIM1 arose and peaked at 3 months after HSCT. (E) Candidate Ags elicit high-titer Ab responses, as indicated by titration studies of serum using ELISA assays. Reactivity remained detectable at dilutions of 1:10 000 (DAPK2) and 1:5000 (PIM1).





**Figure 3. Expression of DAPK2 and PIM1 is enriched in primary MM cells.** (A) DAPK2 and PIM1 have high transcript expression in primary MM BMMCs (gray triangles), but not in normal PBMCs (black diamonds) by gene-specific quantitative real-time PCR. BM specimens contained > 95% tumor by immunohistochemistry. DAPK2, but not PIM1, was also highly expressed in normal CD19<sup>+</sup> B cells (white squares). Bars indicate the median value for transcript expression relative to GAPDH. Statistical significance was determined by 1-sided exact Wilcoxon rank-sum test. (B) Western blotting of cell lysates (20  $\mu$ g of protein per lane) from normal hematopoietic cells and primary MM BMMCs with Ab against either DAPK2 or PIM1 reveals protein expression in 4 (DAPK2) or 3 (PIM1) of 5 primary MM BMMCs. (C) Western blotting of MM cell line lysates (20  $\mu$ g of protein per lane) showed expression of DAPK2 and PIM1 in all tested MM cell lines.

and PIM1 by patient A closely mirrored the reactivity pattern calculated based on significance score, peaking at 3 months after HSCT (Figure 2D), whereas only low or minimal reactivity was detected in pre-HSCT samples. Titration by serial dilution of plasma with maximal reactivity against Ags confirmed the high-titer reactivity against both DAPK2 and PIM1 (1:10 000 and 1:5000, respectively; Figure 2E).

#### DAPK1 and PIM1 are expressed in primary myeloma cells

Tumor-associated Ags are commonly overexpressed in tumor tissue.<sup>15-18</sup> Using quantitative real-time PCR, DAPK2 and PIM1 were enriched in transcript expression in BM from a primary MM patient containing > 95% malignant plasma cells (Figure 3A). Mean relative transcript levels of DAPK2 (normalized to GAPDH) in 5 primary MM samples were 4.8-fold higher than in 4 healthy donor PBMC samples ( $P = .008$ ), and comparable transcript levels were observed between primary MM and 5 healthy donor B-cell samples. Mean relative transcript levels of PIM1 in primary MM samples were 2.1- and 2-fold higher than in healthy donor B cells ( $P = .07$ ) and PBMCs ( $P = .056$ ), respectively. The RNA expression levels of the 4 other candidate Ags were similar between healthy and malignant hematopoietic tissues.

Western blot analysis of PIM1 and DAPK2 expression (representative examples are shown in Figure 3B) showed that DAPK2 was expressed in 10 of 13 primary MM samples tested, and that PIM1 was expressed in 9 of 13 primary MM samples. DAPK2 was also expressed in healthy donor CD19<sup>+</sup> B cells and BMMCs, whereas PIM1 was highly expressed in 1 of 2 healthy donor BMMC samples. Furthermore, PIM1 and DAPK2 were expressed in all 7 MM cell lines (IM9, MC/CAR, MM1S, NCI-H929, OPM1, RPMI 8226, and U266) tested by Western blot analysis (Figure 3C).

#### Ab responses against DAPK2 and PIM1 are associated with effectively treated MM


To determine whether candidate Ags are commonly immunogenic in other patients with effective antimyeloma immunity, we used ELISA to test serial plasma samples from 6 MM patients with effective GVM responses after allogeneic HSCT. All 6 patients had

achieved complete remissions of 2 years or more without clinically evident GVHD. Significant Ab responses to DAPK2 and PIM1 was defined as reactivity greater than 2 SDs above the mean reactivity of 10 normal donors, and was observed in 3 of 6 patients. Two of these 3 patients developed 2-fold or greater increases in Ab reactivity against DAPK2 after allogeneic HSCT, whereas 2 of 3 developed similar increases in reactivity against PIM1 (Figure 4A). Patient 2 showed gradually increasing levels of DAPK2 reactivity from pre-HSCT levels that peaked at 12 months after HSCT (5-fold increase over before HSCT). Patient 3 developed a 2-fold and 4-fold increase in DAPK2 and PIM1 reactivity at 6 months post-HSCT, respectively, that subsequently diminished. Only an early posttransplantation sample was available for patient 5; however, this patient had a striking increase (78-fold) in post-HSCT reactivity against PIM1 compared with pre-HSCT levels.

To further explore the relationship between MM and Ab responses against DAPK2 and PIM1, we performed additional ELISA studies on MM patients before any therapy ("untreated,"  $n = 10$ ), after standard chemotherapy ( $n = 16$ ), and after autologous HSCT ( $n = 10$ ), and in healthy volunteers ( $n = 10$ ). As summarized in Figure 4B, 6 of 16 MM patients treated with standard chemotherapy (37.5%) and 3 of 10 MM patients treated with autologous HSCT (30%) displayed Ab reactivity against DAPK2. In contrast, reactivity against DAPK2 was seen in only 1 of 10 untreated MM patients (10%) and in 0 of 10 normal volunteers (0%). For PIM1, 3 of 16 chemotherapy-treated patients (18.8%) and 1 of 10 patients receiving autologous HSCT (10%) were reactive against the Ag. One of 10 untreated MM patients (10%) and 1 of 10 normal volunteers (10%) had Ab responses to PIM1. Our results demonstrate that humoral immunity against DAPK2 and PIM1 commonly occurs in the setting of treatment for MM.

#### DAPK2 and PIM1 peptides elicit T-cell reactivity in patient A

To determine whether the high-titer B-cell responses to PIM1 and DAPK2 were coordinated with cell-mediated Ag-specific immunity, we tested posttransplantation T cells of patient A for their ability to recognize selected DAPK2- and PIM1-derived 9-mers. Because the patient was HLA-A2 positive, we focused our inquiry on DAPK2- and PIM1-derived peptides that were



**Figure 4. MM treatment is associated with the development of Ab responses against DAPK2 and PIM1.** (A) Plasma samples from 5 MM patients who demonstrated GVM responses (defined as clinical remission > 2 years) without GVHD were tested by ELISA. Three patients (Pt. 2, black bars; Pt. 3, gray bars; and Pt. 5, white bars) had new or markedly increased Ab reactivity to DAPK2 and/or PIM1 after HSCT. The dashed line indicates a cutoff based on 2 SD above the mean of Ab reactivity of 10 normal donors for each Ag. (B) Ab responses against DAPK2 (black bars) and PIM1 (gray bars) are also seen by ELISA in MM patients treated with standard chemotherapy or autologous HSCT, but are minimal in patients with untreated MM or healthy donors.

predicted to bind to this HLA allele. We used consensus predictions of the servers IEDB-ANN, NetMHC-ANN, and MHC-I Multiple Matrix to identify a total of 10 DAPK2-derived (D1-D10) and 7 PIM1-derived (P1-P7) nonameric peptides. All 17 peptides were confirmed to bind to HLA-A2 by the T2-binding assay (Table 3). We therefore tested all 17 peptides against fresh patient PBMCs obtained at 2.5 years after HSCT using an ex vivo stimulation assay.

After 7 days of expansion to predicted peptides, T-cell reactivity to the peptides was assessed using IFN- $\gamma$  secretion (ELISpot assay). As shown in Figure 5A, we observed a 3.8-fold increase in IFN- $\gamma$  secretion in response to stimulation with D1 peptide (8 spot-forming counts [SFCs] per 20 000 cells or 0.038%) compared with the mean SFCs for the other DAPK2-derived peptides (range, 0.6-1.6 SFCs per 20 000 cells [0.003%-0.008%]). Similarly, we observed a striking T-cell response to the PIM1-derived peptide P4 (22 SFCs per 20 000 cells or 0.11%; Figure 5B). Lower levels of reactivity against P1, P2, P5, and P7 were also observed, with frequencies of reactivity in PBMCs of 0.026%, 0.030%, 0.015%, and 0.018%, respectively. The frequency of reactivity for the remainder of the PIM1 peptides was less than 0.005%.

Because of the evidence of marked memory responses in patient A to peptides D1 and P4, subsequent experiments were focused on the characterization of T-cell responses against these 2 predicted peptides. D1- and P4-specific T cells were isolated by peptide-specific tetramers and expanded. These T-cell lines were enriched for D1-reactive (6.6%) and P4-reactive (12%) T cells (Figure 6A).

#### D1- and P4-specific T cells recognize MM cells in an HLA-A2-restricted manner

We undertook further studies using the D1- and P4-reactive T-cell lines to confirm that D1 and P4 represent processed peptides of DAPK2 and PIM1, respectively. As shown in Figure 6B, P4-specific T cells were reactive to both HLA-A2-expressing K562 cells (K562/A2 cells) that were pulsed with exogenous peptide and K562/A2 cells that were nucleofected with plasmid encoding whole PIM1 protein. IFN- $\gamma$  secretion in response to peptide or whole protein was blocked by a class I-blocking Ab. Although D1-specific T cells recognized K562/A2 cells pulsed with exogenous D1 peptide (a process abrogated by class I-blocking Ab), we were unable to evaluate reactivity against DAPK2 overexpressed in K562 cells because forced elevated expression of DAPK2 reproducibly caused K562 cells to undergo apoptosis, as described previously for this molecule.<sup>24</sup>

To further confirm that D1 and P4 peptides are naturally processed and presented by myeloma cells in the context of HLA-A2, we tested 2 other classes of target cells. First, we tested the T-cell lines against 2 HLA-A2<sup>+</sup> (MC/CAR and IM-9) and 2 HLA-A2-negative (OPM-2 and NCI-H929) MM cell lines. Consistent with the HLA-A2-restricted presentation of P4 and D1 by these MM cell lines, we observed reactivity by both D1- and P4-specific T-cell lines against 2 of 2 HLA-A2<sup>+</sup> myeloma cell lines (with reactivity that was blocked by class I-blocking Ab), and against neither of the HLA-A2-negative cell lines (Figure 6C).

Second, we further tested D1- and P4-reactive T cells against CD138-positive cells isolated from BM from primary MM patients (Figure 7). Both D1- and P4-specific T cells were reactive against 4 of 5 HLA-A2-positive BMMC samples from MM patients (average 35 SFCs per 20 000 cells). In contrast, D1- and P4-specific T cells were not reactive against any of the 4 HLA-A2-negative patient samples (average 3.5 SFCs per 20 000 cells) nor the 3 HLA-A2-positive healthy donor BMMC samples. These


**Table 3. Predicted peptides derived from candidate Ags DAPK2 and PIM1**

Protein	ID	Position	Sequence	Consensus rank*	T2 binding	
					FI-0	FI-24
Influenza M1	M1	58	GILGFVFTL	n/a	2.34	2.17
DAPK2	D1	156	MLLDKNIPI	3	3.92	2.28
	D2	316	KLFSFIVSL	6	0.69	0.06
	D3	220	LLSGASPL	10	1.78	0.98
	D4	129	FIKQILDGV	13	0.13	0
	D5	132	QILDGVNYL	17	1.92	0.18
	D6	205	GLEADMWSI	19	1.50	0
	D7	186	NIFGTPEFV	26	2.99	0.07
	D8	81	VLHHNVITL	26	2.05	0.36
	D9	211	WSIGVITYI	29	0.14	0
	D10	212	SIGVITYIL	35	0.23	0
PIM1 (isoform 2)	P1	1	MLLSKINSL	3	1.19	0
	P2	183	KLIDFGSGA	7	0.17	0
	P3	118	LILRPEPV	14	1.56	2.68
	P4	191	ALLKDTVYT	16	1.03	0
	P5	147	FFWQVLEAV	16	0.57	0.04
	P6	265	HLIRWCLAL	21	0.85	0.14
	P7	2	LLSKINSLA	21	1.8	0.39

\*Consensus rank score represents the composite ranking of peptides predicted by all the 3 servers (IEDB-ANN, NetMHC-ANN, and MHC-I multiple matrix). The lower the composite rank number, the higher the predicted binding affinity.

FI-0 indicates the fluorescence intensity at 0 hours; and FI-24, fluorescence intensity at 24 hours.





**Figure 5. DAPK2- and PIM1-derived nonameric peptides elicit T-cell reactivity in post-HSCT PBMCs from patient A.** Fresh post-HSCT PBMCs were stimulated *ex vivo* with 10  $\mu$ M concentrations of individual peptides in the presence of 10  $\mu$ g/mL of IL-7 for 7 days, then tested by ELISpot with peptide-pulsed autologous matured dendritic cells (PBMC:APC ratio = 1:1). (A) T cells from patient A 2.5 years after HSCT show reactivity to the DAPK2-derived peptide D1, but not to other DAPK2-derived peptides. (B) T cells from patient A 2.75 years after HSCT are strongly reactive to the PIM1-derived peptide P4 and weakly reactive to P1, P2, P5, and P7.


results demonstrate that the D1 and P4 immunogenic epitopes are commonly presented on myeloma cells by HLA-A2 molecules.

## Discussion


Syngeneic HSCT for patients with MM produces higher complete remission rates, decreased relapse rates, and improved survival compared with autologous HSCT.<sup>25-27</sup> The clinical superiority of syngeneic over autologous HSCT has been attributed to the absence of tumor contamination<sup>28,29</sup> in the donor graft, and has been hypothesized to also involve the ability to reconstitute normal donor immunity in a MM Ag-rich environment. The results of the present study demonstrate the development of bona fide GVM immunity in the syngeneic setting, providing evidence that immunologic factors contribute to improved outcomes after syngeneic HSCT. Our findings are supported by previous studies of MM patients successfully treated with donor lymphocyte infusion,

an established therapy with well-characterized GVM activity<sup>3,4,7,8</sup> in which potent B- and T-cell responses against TAAs developed in temporal association with effective MM elimination.<sup>15,30</sup> In the present study, disease regression after syngeneic HSCT was likewise associated with potent coordinated B- and T-cell responses against 2 overexpressed MM-associated Ags (DAPK2 and PIM1). Through this system, we identified DAPK2 and PIM1 as potentially promising targets for myeloma-specific immunotherapy, because Ag-specific T cells against both Ags were consistently reactive against HLA-A2<sup>+</sup> primary tumor cells.

Both PIM1 and DAPK2 have been shown previously to play functional roles in lymphoid malignancies, including MM. PIM1 is a known proto-oncogene that participates in the *c-myc*-signaling pathway<sup>31</sup> and has established associations with B-cell lymphomas and other malignancies.<sup>32</sup> Epigenetic silencing of DAPK2, a proapoptotic serine/threonine protein kinase<sup>33</sup> with a tumor-suppressor function, and of related death-associated protein kinases has been observed in multiple neoplasms,<sup>34</sup> including MM,<sup>35</sup> in



**Figure 6. D1- and P4-specific T cells are isolated by tetramer sorting and recognize whole processed and presented Ag.** (A) Patient A CD3<sup>+</sup> T cells were repeatedly stimulated with either D1 or P4 peptide-pulsed T2 cells before staining with peptide-specific tetramer. Tetramer and CD8 double-positive cells were isolated by FACS (representative FACS plots shown). (B) Sorted D1- or P4-positive T cells were tested by ELISpot against K562 cells stably transfected to express HLA-A2 (K562/A2 cells) that were nucleofected to overexpress either DAPK2 or PIM1. As expected, overexpression of DAPK2 induced apoptosis in nucleofected K562 cells.<sup>24</sup> P4-specific T cells recognized processed and presented PIM1, an effect that was blocked by the class I-blocking Ab w6/32. (C) Sorted D1- or P4-positive T cells were also tested against the A2-positive MM cell lines MC/CAR and IM9 and the A2-negative MM cell lines OPM2 and NCI 4929. Both D1- and P4-specific T cells showed reactivity to HLA-A2-positive cell lines, but not to HLA-A2-negative cell lines. IFN- $\gamma$  secretion was blocked by co-incubation with w6/32 Ab.



**Figure 7. D1- and P4-specific CD8 T cells recognize primary MM tissue from HLA-A2-positive patients.** Sorted D1- or P4-positive CD8 T cells were tested by ELISpot against MM BMMCs isolated from fresh BM from HLA-A2-positive donors. D1-specific (A) and P4-specific (B) T cells recognized primary MM BMMCs from HLA-A2-positive donors ( $n = 5$ ), but not healthy HLA-A2-positive BMMCs ( $n = 2$ ) or HLA-A2-negative MM BMMCs ( $n = 4$ ).

which loss of expression appears to worsen clinical outcomes. Based on criteria reported recently by Cheever et al for the selection of optimal Ags for immunotherapy based on function and expression,<sup>36</sup> PIM1 and DAPK2 are both promising targets (supplemental Table 1, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). One criterion not included in this schema, however, is the ability of Ags to elicit immunity in the setting of therapeutic response. This may be an important and desirable characteristic, because the limitations in the ability of T cells with specificities against existing tumor-specific Ags to expand in the posttransplantation setting has been reported, suggesting that chronic antigenic exposure induces replicative senescence.<sup>37</sup>

Whereas the precise mechanism of immunogenicity for DAPK2 and PIM1 remains unclear, the characteristics of these Ags provide some clues. One possible mechanism is the expression of tumor-specific genetic alterations. Malignant plasma cells of MM have been documented to harbor translocations and somatic mutations, albeit at low frequency,<sup>38,39</sup> and these may produce new epitopes that may be recognized by donor T and B cells. We were unable to perform tumor-mutation analysis in our index patient because of no available tumor sample, but mutations in DAPK2 and PIM1 were not noted among a large series of MM samples analyzed by whole-tumor sequencing.<sup>39</sup> Moreover, mutation is unlikely to be the mechanism underlying the immunogenicity of PIM1 and DAPK2, because the immunogenic D1 and P4 A2-binding peptides were derived from wild-type DAPK2 and PIM1 sequences. Conversely, aberrant expression or overexpression of Ags in malignant tissues (which we observed for DAPK2 and PIM1) has been proposed as a factor influencing immunogenicity and other Ab-defined targets.<sup>15-18</sup> Cellular localization may also function to enhance immunogenicity. Recent studies suggest

that proteins complexed with nucleic acid are immunostimulatory,<sup>40</sup> providing a plausible mechanism of immunogenicity for the nuclear protein PIM1. Expression of DAPK2 generates apoptosis,<sup>24</sup> and apoptotic blebs have been reported to possess enriched expression of immunogenic Ags.<sup>41</sup>

Mounting evidence suggests that tumor Ags that elicit coordinated T- and B-cell immunity are viable targets for tumor-specific immunotherapy.<sup>42,43</sup> The phenomenon of cross-presentation, in which immune complexes of Ig and exogenous Ag bind FcγR on dendritic cells and in which internalized Ag is presented on MHC class I molecules,<sup>6</sup> provides a link between B-cell and CD8<sup>+</sup> T-cell responses. Both post-vaccination patient serum<sup>44</sup> and mAbs<sup>45-47</sup> have been shown to enhance cell-mediated tumor immunity, and these mechanisms are potentially relevant for DAPK2 and PIM1.

Our tool kit for generating effective vaccines has increased greatly in recent years, and includes the development of novel vaccine-delivery methods, more potent adjuvants, and highly active checkpoint blockade inhibitors.<sup>48</sup> In this context, defining true tumor-specific Ags is of utmost importance to ensure that potent and focused immune responses leading to effective destruction of tumor cells can be implemented without eliciting autoimmunity. DAPK2 and PIM1, as targets of coordinated humoral and cellular immunity identified in the context of an effective GVM response, are promising targets for future MM-specific immunotherapy.

## Acknowledgments

The authors thank Maris Handley, Suzan Lazo-Kallanian, and John Daley for their assistance with flow cytometry; Dr John Donovan for his vital help in designing the tumor-specific IgH-quantitative PCR assay; and the clinical transplantation team at the Dana-Farber Cancer Institute for their assistance with patient samples.

This work was supported by the Multiple Myeloma Research Foundation and the Pasquarello Tissue Bank. C.J.W. also received a Miles and Eleanor Shore Award, a grant from the National Cancer Institute (5R21CA115043-2), the Early Career Physician-Scientist Award of the Howard Hughes Medical Institute, and a clinical investigator award supported by the Damon-Runyon Cancer Research Foundation (CI-38-07).

## Authorship

Contribution: M.A.B. and C.J.W. designed the study, performed the experiments, analyzed the data, and wrote the manuscript; A.A., W.Z., and L.Z. performed the experiments; G.L.Z., D.N., and V.B. analyzed the data; and Y.-t.T., R.P., N.M., R.J.S., J.R., E.P.A., and K.C.A. provided vital clinical samples.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Catherine J. Wu, MD, Dana-Farber Cancer Institute, Harvard Institutes of Medicine, Rm 416B, 77 Avenue Louis Pasteur, Boston MA 02115; e-mail: cwu@partners.org.

## References

- Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood*. 1990;75(3):555-562.
- Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. *Blood*. 1998;91(10):3671-3680.
- Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. *Blood*. 1997;90(10):4206-4211.
- Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood*. 2005;105(11):4532-4539.
- Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. *Blood*. 2003;102(9):3447-3454.



6. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. *J Exp Med*. 2002; 195(1):F1-F3.
7. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. *Blood*. 1996;87(3):1196-1198.
8. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. *Lancet*. 1996; 347(9004):800-801.
9. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. *N Engl J Med*. 2007;356(11): 1110-1120.
10. Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. *Curr Opin Hematol*. 2002;9(6):497-502.
11. Riddell SR, Murata M, Bryant S, Warren EH. Minor histocompatibility antigens—targets of graft versus leukemia responses. *Int J Hematol*. 2002; 76(suppl 2):155-161.
12. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. *Blood*. 2007;109(4): 1355-1362.
13. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. *Adv Immunol*. 2006;90:133-173.
14. Nishida T, Hudecek M, Kostic A, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. *Clin Cancer Res*. 2009;15(14):4759-4768.
15. Bellucci R, Wu CJ, Chiaretti S, et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. *Blood*. 2004; 103(2):656-663.
16. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. *Cancer Res*. 2010;70(3):906-915.
17. Marina O, Hainz U, Biernacki MA, et al. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. *Cancer Res*. 2010;70(4): 1344-1355.
18. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. *J Clin Invest*. 2000;106(5):705-714.
19. Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonic stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. *J Exp Med*. 2007;204(4): 831-840.
20. Marina O, Biernacki MA, Brusic V, Wu CJ. A concentration-dependent analysis method for high density protein microarrays. *J Proteome Res*. 2008;7(5):2059-2068.
21. Marina O, Duke-Cohan JS, Wu CJ. A coprecipitation-based validation methodology for interactions identified using protein microarrays. *Methods Mol Biol*. 2011;723:239-254.
22. Ladetto M, Donovan JW, Harig S, et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. *Biol Blood Marrow Transplant*. 2000;6(3):241-253.
23. Lim JS, Kim S, Lee HG, Lee KY, Kwon TJ, Kim K. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling. *Mol Immunol*. 1996;33(2):221-230.
24. Tur MK, Neef I, Jost E, et al. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. *J Immunother*. 2009;32(5):431-441.
25. Bashey A, Perez WS, Zhang MJ, et al. Comparison of twin and autologous transplants for multiple myeloma. *Biol Blood Marrow Transplant*. 2008;14(10):1118-1124.
26. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. *Bone Marrow Transplant*. 1996;18(3):527-531.
27. Gahrton G, Svensson H, Björkstrand B, et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 1999;24(7):741-745.
28. Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. *J Cancer Res Clin Oncol*. 2009;135(4): 637-642.
29. Ladetto M, Omede P, Sametti S, et al. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. *Exp Hematol*. 2002;30(6):529-536.
30. Bellucci R, Alyea EP, Chiaretti S, et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. *Blood*. 2005;105(10):3945-3950.
31. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. *Nat Cell Biol*. 2007;9(8):932-944.
32. Shah N, Pang B, Yeoh KG, et al. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. *Eur J Cancer*. 2008; 44(15):2144-2151.
33. Cohen O, Feinstein E, Kimchi A. DAP-kinase is a Ca<sup>2+</sup>/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. *EMBO J*. 1997;16(5):998-1008.
34. Kissil JL, Feinstein E, Cohen O, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. *Oncogene*. 1997;15(4):403-407.
35. Ng MH, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. *Clin Cancer Res*. 2001;7(6):1724-1729.
36. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin Cancer Res*. 2009;15(17): 5323-5337.
37. Beatty GL, Smith JS, Reshef R, et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8<sup>+</sup> T cells after allogeneic stem cell transplantation. *Clin Cancer Res*. 2009;15(15):4944-4953.
38. Thomas RK, Baker AC, Debiase RM, et al. High-throughput oncogene mutation profiling in human cancer. *Nat Genet*. 2007;39(3):347-351.
39. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature*. 2011;471(7339):467-472.
40. Lin Y, Zhang L, Cai AX, et al. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. *J Clin Invest*. 2011;121(4): 1574-1584.
41. Suber T, Rosen A. Apoptotic cell blebs: repositories of autoantigens and contributors to immune context. *Arthritis Rheum*. 2009;60(8):2216-2219.
42. Zhang W, Choi J, Zeng W, et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. *Clin Cancer Res*. 2010;16(10):2729-2739.
43. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. *Blood*. 2007;109(3):1103-1112.
44. Jäger E, Karbach J, Gnjatic S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. *Proc Natl Acad Sci U S A*. 2006;103(39):14453-14458.
45. Dhodapkar KM, Krasovskiy J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. *J Exp Med*. 2002;195(1): 125-133.
46. Saenger YM, Li Y, Chiou KC, et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. *Cancer Res*. 2008;68(23):9884-9891.
47. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. *Proc Natl Acad Sci U S A*. 2007;104(21):8947-8952.
48. DeLuca DS, Marina O, Ray S, Zhang GL, Wu CJ, Brusic V. Data processing and analysis for protein microarrays. *Methods Mol Biol*. 2011;723:337-347.



**blood**®

2012 119: 3142-3150

doi:10.1182/blood-2011-11-388926 originally published  
online January 20, 2012

## **Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation**

Melinda A. Biernacki, Yu-tzu Tai, Guang Lan Zhang, Anselmo Alonso, Wandi Zhang, Rao Prabhala, Li Zhang, Nikhil Munshi, Donna Neuberg, Robert J. Soiffer, Jerome Ritz, Edwin P. Alyea, Vladimir Brusic, Kenneth C. Anderson and Catherine J. Wu

---

Updated information and services can be found at:

<http://www.bloodjournal.org/content/119/13/3142.full.html>

Articles on similar topics can be found in the following Blood collections

[Lymphoid Neoplasia](#) (2370 articles)

[Multiple Myeloma](#) (338 articles)

[Transplantation](#) (2160 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:

[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>